11.27
-0.46(-3.92%)
Currency In USD
| Previous Close | 11.73 |
| Open | 11.55 |
| Day High | 11.7 |
| Day Low | 11.26 |
| 52-Week High | 19.29 |
| 52-Week Low | 9.41 |
| Volume | 1.89M |
| Average Volume | 1.31M |
| Market Cap | 1.81B |
| PE | -140.87 |
| EPS | -0.08 |
| Moving Average 50 Days | 12.48 |
| Moving Average 200 Days | 12.65 |
| Change | -0.46 |
If you invested $1000 in Certara, Inc. (CERT) since IPO date, it would be worth $295.96 as of March 11, 2025 at a share price of $11.27. Whereas If you bought $1000 worth of Certara, Inc. (CERT) shares 3 years ago, it would be worth $594.41 as of March 11, 2025 at a share price of $11.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
GlobeNewswire Inc.
Mar 05, 2025 9:15 PM GMT
McKemey joins Certara to accelerate growth of its strategic drug development solutionsRADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Jan 29, 2025 9:15 PM GMT
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market cl
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Jan 15, 2025 12:55 PM GMT
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 millionConfirms Adjusted EBITDA within Guidance Range of $120 million to $124 million RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model